[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649365":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":42,"collaborators":44,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":70,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Shanghai UniXell Biotechnology Co., Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"UX-DA003","EXPERIMENTAL",null,[13],"Drug: UX-DA003",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","UX-DA003 (Human Allogeneic iPSC-derived Midbrain Dopaminergic Progenitor cells) is used for treating patients with PD via implanting into bilateral putamina under stereotactic neurosurgery.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Jun Liu, MD, PhD","CONTACT","+86-21-64370045","jly0520@hotmail.com",[26],{"facility":27,"status":11,"city":28,"state":11,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","Shanghai","200025","China","CN",{"type":33,"coordinates":34},"Point",[35,36],121.45806,31.22222,{"lat":36,"lon":35},[39,40],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},{"name":21,"role":41,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":43,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[45],{"name":46,"class":47},"Ruijin Hospital","OTHER","100649365","phase-1-phase-iii-clinical-trial-of-ux-da003-injection-for-the-treatment-of-patients-with-parkinsons-disease-100649365",false,"NCT07733349","Phase I\u002FII Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease","Phase I\u002FII Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of UX-DA003 Injection in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Aged between 30 and 75 years, regardless of gender\n* Diagnosed with Parkinson's disease conforming to relevant clinical diagnostic standards with a medical history of 5-20 years\n* Having received standard anti-PD treatment and been given optimal anti-PD treatment under the guidance of the investigator, but the efficacy has significantly declined\n* Good response to levodopa medications, the levodopa challenge test (LCT) shows that the maximum improvement rate of the UPDRS-III score exceeds 30%\n* The modified H\\&Y staging (Off period) of ≥2.5 and ≤4, with total daily \"off\" time \\>2 hours\n* Stable dose of anti-Parkinson' disease drugs for at least 4 weeks prior to screening\n* Good physical condition or stable concomitant diseases\n\nExclusion Criteria:\n\n* The subjects with atypical Parkinson's syndrome or secondary Parkinson's syndrome\n* Severe systemic diseases or functional impairments\n* Evidence of active infection or chronic infection, which may pose a risk to the subject\n* Severe concomitant central nervous system diseases or severe cognitive and psychiatric disorders\n* Subjects with a history of brain injuries, cerebral vascular malformations, hydrocephalus, brain tumors, or other brain damages as shown by previous Head CT\u002FMRI scans, or subjects with abnormal brain imaging in the striatum or other brain regions that significantly increase surgical risks\n* Subjects who have participated in clinical trials for stem cell therapy or gene therapy for Parkinson's disease, or have participated in other interventional clinical trials within the last 3 months\n* Subjects with a history of severe allergies or hypersensitivity reactions, known hypersensitivity to the investigational drug or its ancillary materials, or intolerance to them\n* Pregnant or breastfeeding women","ALL","30 Years","75 Years",{"count":59,"type":60},12,"ESTIMATED","INTERVENTIONAL",[63,64],"PHASE1","PHASE2","This clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.",[67],"Parkinson's Disease",[69,67],"allogeneic iPSC derived mDAPs","NOT_YET_RECRUITING","2026-07-24",{"date":73,"type":74},"2026-07-29","ACTUAL",{"date":76,"type":60},"2026-08-03",{"date":78,"type":60},"2032-08-31",{"name":5,"class":6},1]